Elucent Medical Revolutionizes Surgical Navigation with $42.5M Funding
April 18, 2024, 3:53 am
Location: United States, Minnesota, Eden Prairie
Employees: 11-50
Founded date: 2013
Total raised: $42.5M
Elucent Medical, a cutting-edge medical technology company based in Eden Prairie, MN, has secured $42.5M in Series C funding to advance its innovative surgical navigation technologies. Led by Vensana Capital and RC Capital, with participation from existing investors, this funding will drive the development and commercialization of Elucent's EnVisio® and SmartClip® technologies, designed to enhance precision in oncologic surgery.
Elucent's flagship technologies, EnVisio® and SmartClip®, harness the power of In-Site Spatial Intelligence (iSI) to provide surgeons with real-time, in-situ spatial guidance during critical procedures. By transforming standard surgical instruments into intelligent tracking devices, these technologies enable surgeons to operate with unparalleled accuracy, revolutionizing the standard of care in soft tissue oncologic procedures.
While initially optimized for breast cancer surgery, EnVisio® is expanding its platform to address a wide range of soft tissue oncology surgeries. Elucent is also developing new products to assist surgeons in achieving margin-negative resections in lung and other soft tissue clinical applications, seamlessly integrating with existing surgical tools and minimally invasive solutions.
Jason Pesterfield, President and CEO of Elucent Medical, expressed pride in securing this substantial funding, emphasizing the company's mission to transform surgical navigation by elevating the standard of care in oncologic procedures. With the support of investors, Elucent is poised to accelerate the commercialization of its groundbreaking technologies, empowering healthcare providers with innovative tools to improve patient outcomes.
Elucent's flagship technologies, EnVisio® and SmartClip®, harness the power of In-Site Spatial Intelligence (iSI) to provide surgeons with real-time, in-situ spatial guidance during critical procedures. By transforming standard surgical instruments into intelligent tracking devices, these technologies enable surgeons to operate with unparalleled accuracy, revolutionizing the standard of care in soft tissue oncologic procedures.
While initially optimized for breast cancer surgery, EnVisio® is expanding its platform to address a wide range of soft tissue oncology surgeries. Elucent is also developing new products to assist surgeons in achieving margin-negative resections in lung and other soft tissue clinical applications, seamlessly integrating with existing surgical tools and minimally invasive solutions.
Jason Pesterfield, President and CEO of Elucent Medical, expressed pride in securing this substantial funding, emphasizing the company's mission to transform surgical navigation by elevating the standard of care in oncologic procedures. With the support of investors, Elucent is poised to accelerate the commercialization of its groundbreaking technologies, empowering healthcare providers with innovative tools to improve patient outcomes.